Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LYN-057 Safety and Gastric Retention in Healthy Adults
NCT03711825Phase 1Completed
- Sponsor
- Lyndra Therapeutics
- Start
- Sep 2018
- Primary completion
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of memantine in Alzheimer's disease (AD), sponsored by Lyndra Therapeutics. Primary endpoints: Gastric retention by imaging assessment by MRI, Gastric retention by imaging assessment by abdominal U/S and 1 more. Started Sep 2018; status: completed.
02
Drugs
memantine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT03711825.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03711825.